00:26 , Apr 15, 2017 |  BioCentury  |  Product Development

Outside factors

This year could see the first regulatory submission from a coming wave of new therapies for hemophilia prophylaxis that do not simply replace missing clotting factors, which has been the standard for care for decades....
07:00 , Jul 16, 2015 |  BC Innovations  |  Translation in Brief

Bayer's replacement antibody

Bayer AG 's new mAb could treat hemophilia patients who have neutralizing antibodies against coagulation factors, and avoid the frequent IV infusions of factor replacement therapy. In a departure from Bayer AG's historical focus on...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Bayer preclinical data

In a mouse model of hemophilia A, single doses of 0.6-2 mg/kg IV BAY 1093884 given prior to induced bleeding led to a 50% survival rate for up to 6 days vs. a 25% survival...